You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 270 No. 21, December 1, 1993 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Council Report
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Silicone Gel Breast Implants

Council on Scientific Affairs, American Medical Association; Yank D. Coble, Jr, MD; E. Harvey Estes, Jr, MD; C. Alvin Head, MD; Mitchell S. Karlan, MD; William R. Kennedy, MD; Patricia Joy Numann, MD; William C. Scott, MD; W. Douglas Skelton, MD; Richard M. Steinhilber, MD; Jack P. Strong, MD; Katherine A. Schneider; Henry N. Wagner, Jr, MD; Jerod M. Loeb, PhD; Robert C. Rinaldi, PhD; Donald R. Bennett, MD, PhD

JAMA. 1993;270(21):2602-2606.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

AT THE 1991 Annual Meeting, Resolution 259 was referred by the Board of Trustees to the Council on Scientific Affairs (CSA) for a report on the evaluation of the safety of breast implants. The recommendations of Report M prepared by the CSA were adopted as amended by the American Medical Association (AMA) House of Delegates at the Interim Meeting in 1991 in lieu of Resolution 259 (A-91) and Resolution 521 (I-91) and the remainder of the Report was filed (Policy 525.984, AMA Policy Compendium). Report M described the Food and Drug Administration (FDA) regulatory history of breast implant devices through August 1991. Because of continuing developments, including a voluntary moratorium on their use by the FDA in November 1991, the Council elected to provide a follow-up report (Report C) on this subject. Report C covers the continuing FDA regulatory history through October 1992 and

See also pp 2607 and 2608. . . . [Full Text PDF of this Article]


Author Affiliations

(Vice-Chair), Jacksonville, Fla; (Chairman), Durham, NC; (Resident Representative), Tucker, Ga; Beverly Hills, Calif; Minneapolis, Minn; Syracuse, NY; Tucson, Ariz; Macon, Ga; Cleveland, Ohio; New Orleans, La; (Medical Student Representative), New York, NY; Baltimore, Md

From the Council on Scientific Affairs, American Medical Association, Chicago, III.


Footnotes

Dr Bennett was an employee of Dow Corning Corp from 1965 until his resignation in 1974. Since 1991, he has received a Dow pension of $315 per month.

The recommendations of Report C of the Council on Scientific Affairs were adopted at the 1992 House of Delegates Interim Meeting and the report was filed.

This report is not intended to be construed or to serve as a standard of medical care. Standards of medical care are determined on the basis of all the facts and circumstances involved in an individual case and are subject to change as scientific knowledge and technology advance and patterns of practice evolve. This report reflects the scientific literature as of December 1992.

Reprint requests to the Group on Science, Technology, and Public Health, Council on Scientific Affairs, American Medical Association, 515 N State St, Chicago, IL 60610 (Dr Loeb).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.